Loading
A phase 3 trial of Pertuzumab and Trastuzumab in advanced solid tumours, run by Hoffmann-La Roche, active and no longer recruiting.
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial is a phase 3 interventional study registered as NCT02320435 by Hoffmann-La Roche, with 154 participants enrolled, started 2015-02-02 and due to reach its primary completion in 2026-12-31. Interventions recorded: Pertuzumab, Trastuzumab and Other Combination Anti-Cancer Therapies.
Shares Flatiron Health (Roche), Pertuzumab, Trastuzumab, Monoclonal antibodies and the tag pipeline.
Shares Pertuzumab, Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pertuzumab, Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pertuzumab, Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Flatiron Health (Roche), Trastuzumab, Monoclonal antibodies and the tag pipeline.
Shares Pertuzumab, Monoclonal antibodies and the tag pipeline.
Shares Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.